Comparison of the hypoglycemic effect of sitagliptin versus the combination of mitiglinide and voglibose in drug-naive Japanese patients with type 2 diabetes

被引:6
|
作者
Ohta, Akio [1 ]
Ohshige, Toshihiko [1 ]
Sakai, Kensuke [1 ]
Nakamura, Yuta [1 ]
Tenjin, Ayumi [1 ]
Tsukiyama, Shuichi [1 ]
Terashima, Yuko [1 ]
Matsubara, Fumiaki [1 ]
Kawata, Takehiro [1 ]
Nagai, Yoshio [1 ]
Tanaka, Yasushi [1 ]
机构
[1] St Marianna Univ, Sch Med, Div Endocrinol & Metab, Dept Internal Med,Miyamae Ku, Kawasaki, Kanagawa 2168511, Japan
关键词
1,5-anhydroglucitol; glycoalbumin; mitiglinide; sitagliptin; voglibose; DIPEPTIDYL PEPTIDASE-4 INHIBITOR; ALPHA-GLUCOSIDASE INHIBITORS; FASTING PLASMA-GLUCOSE; FIXED-DOSE COMBINATION; INSULIN-SECRETION; POSTPRANDIAL HYPERGLYCEMIA; NATEGLINIDE; SULFONYLUREAS; RESISTANCE; RISK;
D O I
10.1517/14656566.2013.842554
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Objective: The postprandial glucose (PPG) level is reduced by alpha-GIs, glinides and DPP4Is through different pharmacological actions. The aim of this study was to compare the effect of sitagliptin (S) versus that of the combination of mitiglinide and voglibose (M+V) on markers of glycemic control. Research design and methods: A randomized cross-over trial was performed in 20 patients with drug-naive type 2 diabetes. The patients were randomized to receive S (50 mg/day) or M+V (1 tablet 3 times daily). Treatment was continued for 8 weeks, after which they were switched to the other regimen and treated for another 8 weeks. At baseline, after the first regimen, and after the second regimen, a meal test was performed. Main outcome measures: The markers of glycemic control were examined. Results: Reduction of glucose excursion was significantly greater with M+V than with S. HbA(1c) did not change with either regimen. However, 1,5-anhydroglucitol showed a significant increase from baseline with both regimens (7.9 +/- 4.3 mu g/ml at baseline vs. 10.6 +/- 5.5 with S, p < 0.05 and 15.1 +/- 6.2 with M+V, p < 0.01). Compared with baseline, glycoalbumin was significantly reduced by M+V, but not S (19.6 +/- 2.9% at baseline vs. 17.3 +/- 3.8% with M+V, p < 0.05). Conclusion: M+V achieved better control of PPG excursion than S.
引用
收藏
页码:2315 / 2322
页数:8
相关论文
共 50 条
  • [21] Additive Postprandial Glucose-Lowering Effects of Mitiglinide and Sitagliptin in Patients with Type 2 Diabetes Mellitus
    Jung, Jin Ah
    Kaku, Kohei
    Kim, Jae Hyeon
    Kim, Jung-Ryul
    Ko, Jae-Wook
    Lee, Soo-Youn
    Huh, Wooseong
    ADVANCES IN THERAPY, 2013, 30 (11) : 1018 - 1029
  • [22] Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes
    Yamaguchi, Masayuki
    Saji, Takami
    Mita, Sachiko
    Kulmatycki, Kenneth
    He, Yan-Ling
    Furihata, Kenichi
    Sekiguchi, Kaneo
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS, 2013, 51 (08) : 641 - 651
  • [23] Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
    Kubota, Akira
    Maeda, Hajime
    Kanamori, Akira
    Matoba, Kiyokazu
    Jin, Yasuyuki
    Minagawa, Fuyuki
    Obana, Mitsuo
    Iemitsu, Kotaro
    Ito, Shogo
    Amamiya, Hikaru
    Kaneshiro, Mizuki
    Takai, Masahiko
    Kaneshige, Hideaki
    Hoshino, Kazuhiko
    Ishikawa, Masashi
    Minami, Nobuaki
    Takuma, Tetsuro
    Sasai, Nobuo
    Aoyagi, Sachio
    Kawata, Takehiro
    Mokubo, Atsuko
    Takeda, Hiroshi
    Honda, Shin
    Machimura, Hideo
    Motomiya, Tetsuya
    Waseda, Manabu
    Naka, Yoshikazu
    Tanaka, Yasushi
    Terauchi, Yasuo
    Matsuba, Ikuro
    JOURNAL OF DIABETES INVESTIGATION, 2012, 3 (06) : 503 - 509
  • [24] Impact of Voglibose on the Pharmacokinetics of Dapagliflozin in Japanese Patients with Type 2 Diabetes
    Akira Imamura
    Masahito Kusunoki
    Shinya Ueda
    Nobuya Hayashi
    Yasuhiko Imai
    Diabetes Therapy, 2013, 4 : 41 - 49
  • [25] A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes
    Son, Jang-Won
    Lee, In-Kyu
    Woo, Jeong-taek
    Baik, Sei Hyun
    Jang, Hak Chul
    Lee, Kwan Woo
    Cha, Bong Soo
    Sung, Yeon-Ah
    Park, Tae Sun
    Yoo, Soon-Jib
    Yoon, Kun-Ho
    ENDOCRINE JOURNAL, 2015, 62 (12) : 1049 - 1057
  • [26] Efficacy and safety of sitagliptin added to metformin and insulin compared with voglibose in patients with newly diagnosed type 2 diabetes
    Shi, Chunhong
    Zhang, Ru
    Bai, Ran
    Liu, Dan
    Wang, Yongbo
    Zhang, Xueyang
    Wang, Hao
    Du, Jianling
    CLINICS, 2019, 74
  • [27] Comparison of healthcare resource utilization and costs in patients with type 2 diabetes initiating dapagliflozin versus sitagliptin
    Parker, Emily D.
    Wittbrodt, Eric T.
    McPheeters, Jeffrey T.
    Frias, Juan P.
    DIABETES OBESITY & METABOLISM, 2019, 21 (02) : 227 - 233
  • [28] Comparison of Glycemic Excursion Using Flash Continuous Glucose Monitoring in Patients with Type 2 Diabetes Mellitus Before and After Treatment with Voglibose
    Kasthuri, Selvam
    Poongothai, Subramani
    Anjana, Ranjit Mohan
    Selvakumar, Jayvel
    Muthukumar, Subramaniam
    Kayalvizhi, Sengottuevel
    Tariq, Syed
    Honey, Evangelin
    Gupta, Prasanna Kumar
    Venkatesan, Ulagamathesan
    Mohan, Viswanathan
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (03) : 213 - 220
  • [29] Comparison of Glycemic Variability in Patients with Type 2 Diabetes Given Sitagliptin or Voglibose: A Continuous Glucose Monitoring-Based Pilot Study
    Seo, Chiaki
    Sakamoto, Masaya
    Nishimura, Rimei
    Tsujino, Daisuke
    Ando, Kiyotaka
    Morimoto, Aya
    Utsunomiya, Kazunori
    DIABETES TECHNOLOGY & THERAPEUTICS, 2013, 15 (05) : 378 - 385
  • [30] Improvement of glycaemic control by nateglinide decreases systolic blood pressure in drug-naive patients with type 2 diabetes
    Gonzalez-Clemente, J. -M.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2008, 38 (03) : 174 - 179